Fuxal

Quick links to important sections

Fuxal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fuxal

Quick Facts

Property Description
Active ingredient Nitrofural (INN)
Form Solution, Ointment, or Cream
Pharmacological class Antiseptic and Topical Anti-infective
Common use Local control of bacterial contamination
Origin Synthetic (Nitrofuran derivative)

Fuxal: Definition and Pharmacological Classification

The medication known by the trade name Fuxal contains the active ingredient Nitrofural (INN, also known as nitrofurazone), which is a completely synthetic compound. It is formally categorized as an antiseptic and topical anti-infective agent, specifically belonging to the Nitrofuran derivative chemical group. This classification places it among agents intended to prevent microbial growth on external body surfaces. The World Health Organization (WHO) includes Nitrofural in the Anatomical Therapeutic Chemical (ATC) classification system. The agent functions to maintain a clean surface environment for compromised skin.

Composition, Forms, and External Application

Nitrofural is consistently formulated as a single-ingredient product, with only the one active compound present for therapeutic effect. The active substance is typically compounded into several versatile dosage forms optimized for topical application, including a sterile solution, a cream, or an ointment. The preparation is distinctive in its formulation, often utilizing bases designed for stability and patient comfort on wounded tissue. Since the route of administration is strictly external, these preparations are engineered to maximize local action and minimize systemic absorption, which is associated with a favorable safety profile compared to systemic agents.

General Purpose of the Local Anti-Infective

The overarching purpose of using a medication containing Nitrofural is to achieve localized antimicrobial protection by controlling bacterial contamination. The core function of the active substance is to interfere with specific bacterial enzyme systems crucial for cell survival and metabolism. This action helps to ensure that pathogens cannot easily thrive in the applied area. A typical use scenario involves cleaning and protecting minor lacerations or skin abrasions where there is a risk of infection. The resulting efficacy against a spectrum of external bacterial threats, including both Gram-positive and Gram-negative organisms, supports the body's natural processes by reducing the microbial load.

What side effects are possible with Fuxal?

Possible side effects and safety information

The official safety profile for topical Nitrofural is structured around adverse reactions that are primarily localized and specific safety constraints documented by regulatory authorities. The most frequent safety concern is a localized dermal reaction, which is typically confined to the application site.

Adverse Reactions Scope

Adverse Effect Category Official Regulatory Note
Skin and Subcutaneous Tissue The most common documented adverse effect is contact dermatitis, with other less common reactions including pruritus (itching), rash, and swelling.
Overall Frequency Historical clinical data indicates an overall incidence rate of skin reactions of approximately 1.1%, classifying these effects as generally less common.
Serious Reactions Severe contact dermatitis is documented. Systemic toxicity from excipient polyethylene glycol absorption is a rare but serious potential risk, especially in high-risk patients.

Safety Constraints and Special Populations

Formal contraindications exist for individuals with a known history of hypersensitivity to Nitrofural or any component of the formulation.

The risk of serious systemic toxicity is heightened when the preparation is used over a large total body surface area or under occlusive dressings. This systemic risk is particularly relevant to patients with pre-existing renal impairment (kidney disease) due to potential excipient absorption.

Regarding pregnancy, regulatory documentation states that safe use has not been established and use is therefore restricted to situations where the potential benefit clearly outweighs the potential risk. Furthermore, the official labeling contains a safety note concerning findings from high-dose animal carcinogenicity studies, though the relevance to human topical use remains officially unknown.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Overdose Presentations: The active ingredient in Fuxal (Nitrofural) is documented in official labeling as not significantly toxic in man by topical application. Overdose, resulting from excessive application, is primarily manifested as an exacerbation of local adverse reactions. These regulator-documented signs include sensitization, localized irritation, and the potential development of generalized allergic skin reactions. In rare instances, excessive exposure has been linked to severe contact dermatitis.

Population-Specific Considerations: A distinct, officially documented risk is related to the polyethylene glycol vehicle used in certain formulations. In patients with known or suspected renal impairment, systemic absorption of this vehicle from large, compromised skin areas may lead to complications such as progressive renal impairment and metabolic acidosis. This potential toxicity requires clinical monitoring.

Official Emergency Actions: In the event of suspected overdose or excessive application, the regulatory guidance states that the product should be discontinued. Treatment is described as being strictly symptomatic and supportive, which includes the procedural step to cleanse the affected area with mild soap and water. Urgent medical attention is required if signs of severe irritation, persistent sensitization, or superinfection develop, necessitating the prompt institution of appropriate therapy as stated in the official prescribing information.

Therapeutic Uses of Fuxal

What Fuxal Treats: Main Uses and Benefits

The medication Fuxal (Nitrofural) is a topical anti-infective generally used in clinical and real-world scenarios for managing localized bacterial contamination in compromised skin. Its primary utility plays a role in managing the bacterial component of wounds and lesions to support natural healing processes. The medicine is applied as an adjunctive therapy in conditions where bacterial challenge is significant.

Fuxal is commonly used to help with conditions marked by increased discomfort or tension, including the adjunctive treatment of second- and third-degree burns, management of infected dermatoses, pyodermas, and protection of surgical sites such as skin graft donor sites.

Quick Fact: Relief for Bacterial Contamination Primary Use Key Benefit
Major Burns Contributes to the process of tissue repair by reducing microbial obstacles.
Grafting Assists in maintaining stability during the healing of the graft site.

The use of topical anti-infectives supports a stable environment for healing. The medicine supports general well-being during symptomatic phases and may assist with maintaining functional stability in the affected area. This is relevant in contexts involving heightened systemic burden.

Eligibility and Restrictions for Use

Who Can and Cannot Use Fuxal (Nitrofural)

Eligibility for Fuxal is strictly defined by regulatory labeling based on a patient's sensitivity status, age, organ function, and reproductive status. This information is derived from official government sources and does not constitute medical advice.


Official Eligibility Constraints

Classification Population Group Regulatory Status
Contraindicated Patients with known prior sensitization to nitrofurazone or to any component of the formulation. Absolute prohibition due to hypersensitivity.
Conditional Use Patients with known or suspected renal dysfunction. Use with caution is required for polyethylene glycol-containing formulations (e.g., ointment) due to potential excipient absorption.
Not Recommended Pregnant women and women of child bearing potential. Safe use has not been established.
Not Recommended Lactating/Breastfeeding Mothers. A risk to the new-born cannot be excluded.
Use Not Established Pediatric Population (Children). Safety and efficacy have not been established in this age group.

Summary of Use

Fuxal is officially labeled for use primarily in adult patients as adjunctive therapy for approved indications. Use in children, pregnant women, and lactating mothers is limited due to a lack of established safety data, and the medication is strictly prohibited for anyone with a known allergy to its active ingredient, nitrofurazone.

What should I know about interactions with other medicines?

Fuxal (which is fluoxetine) can interact with a wide variety of other medicines and products, potentially increasing the risk of side effects or altering the effects of either drug. It is crucial to inform your healthcare provider about all prescription, over-the-counter, and herbal products you are currently taking, or plan to take.

Major Interactions

Certain combinations are highly clinically significant and should generally be avoided due to the risk of serious conditions like Serotonin Syndrome or heart rhythm abnormalities (QT prolongation). These include, but are not limited to:

  • Monoamine Oxidase Inhibitors (MAOIs): Including phenelzine, selegiline, isocarboxazid, and the antibiotic linezolid. A washout period of several weeks is required when switching between Fuxal and an MAOI.
  • Other Serotonergic Drugs: Including other SSRIs, SNRIs, tricyclic antidepressants (TCAs), triptans for migraines, lithium, and the herbal supplement St. John's Wort.
  • Certain Antipsychotics and Antiarrhythmics: Such as pimozide, thioridazine, and quinidine, due to the risk of QT prolongation.

Moderate Interactions

Combinations listed below may require dose adjustments or extra monitoring due to an increased risk of side effects, particularly bleeding or sedation:

Drug Class Potential Outcome
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., ibuprofen, aspirin) and Blood Thinners (e.g., warfarin, apixaban) Increased risk of bleeding, particularly gastrointestinal bleeding.
Benzodiazepines (e.g., diazepam, alprazolam) Increased blood levels of the benzodiazepine, leading to increased sedation.
Tramadol or other Opioid Pain Relievers Increased risk of Serotonin Syndrome and potential reduction in opioid effectiveness.

It is also advised to avoid alcohol consumption while taking Fuxal, as it may worsen central nervous system side effects like drowsiness and reduced alertness.

Mechanism of Action

Bacterial Enzyme Bioactivation and Prodrug Reduction

The mechanism begins with the obligatory bioactivation of the Nitrofural molecule (a prodrug) by specific bacterial enzymes known as nitroreductases. This initial step is critical as it converts the drug into highly reactive electrophilic intermediates. This reliance on bacterial enzymes for activation ensures the selective generation of toxic species predominantly within the pathogen, which is the necessary first step toward the localized anti-infective physiological consequence.


Multi-Target Macromolecular Damage

The intermediates generated through bioactivation act as cellular toxins, rapidly and nonspecifically covalently binding to multiple essential bacterial components, including DNA, RNA, ribosomes, and key metabolic enzymes. This simultaneous, multi-site damage prevents the cell from performing replication, protein synthesis, and energy generation. The resulting physiological effect is the irreversible bactericidal killing of susceptible organisms, which contributes to the reduction of the local microbial load.


Mechanistic Constraints and Resistance

The mechanism's susceptibility is fundamentally limited by the pathogen's expression of the activating enzyme. Bacterial resistance occurs when strains lose or significantly downregulate the required nitroreductase enzymes, functionally preventing the drug from being converted into its toxic form. This specific constraint is a factor that restricts the development of resistance within the mechanism, resulting in an anti-infective physiological consequence against susceptible strains.

Dosage and Administration Information

How Fuxal is Used: Administration and Usage

Fuxal (Nitrofural) is a topical anti-infective administered exclusively via the topical route for local external use on the skin. The medication is available in various dosage forms, including a 0.2% ointment, cream, or solution.

Standard Dosing and Frequency

The established principle of dosing requires applying a sufficient amount to ensure the entire affected area is covered, rather than specifying a fixed quantity. This usage pattern is characteristic of its topical applications.

The standard application schedule is typically once daily. However, reapplication frequency may be adjusted to once daily or once weekly depending on the specific clinical protocol and the type of dressing technique being used for the wound. This medication is intended for short-term use and should be discontinued once the need for topical antimicrobial application is resolved.

Application Methods and Procedural Notes

The preparation may be applied in two primary ways:

  1. Direct Application: Applying a thin layer directly onto the lesion.
  2. Dressing Technique: Spreading the preparation onto sterile gauze, which is then used to cover the affected site.

Population-Specific Use Constraint

While fixed dose adjustments are not common for this topical agent, a specific consideration relates to the formulation vehicle for specific populations. Forms such as the solution or soluble dressing may contain polyethylene glycols (PEG). In patients with known or suspected kidney impairment, the use of PEG-containing forms involves caution, especially over large damaged skin areas, due to the potential for absorption and accumulation. Use in pediatric patients is determined by clinical assessment.

Recent Clinical Evidence

Fuxal: Recent Clinical Evidence


Mechanism of Investigation

Hypotheses regarding how the drug functions include the exploration of its influence on multiple pathways associated with the condition. Studies have investigated its potential effect on inflammatory markers and specific cellular responses. The research documented specific parameters in these areas, forming the basis for further clinical investigation.

Clinical Evaluation in Acute Symptoms

Multiple Randomized Controlled Trials (RCTs) and meta-analyses have investigated specific clinical endpoints in cases of acute flare-ups. Research has examined its investigation in the context of acute symptoms. Studies have evaluated whether the drug influenced the measurement of pain and inflammation when compared to a placebo.

Clinical trials documented whether the drug was associated with changes in predefined clinical scores over a 12-week period. The primary endpoint in these studies was the change from baseline in validated scoring systems. This research included assessment of the investigational product.

Exploration of Long-Term Effects

Cohort studies and post-market surveillance programs have been implemented to explore the long-term impact of the drug. Research has also explored the measurement of quality of life metrics for long-term users.

The long-term safety profile has been the subject of several studies. Side effects have been documented in studies. The potential for liver-related findings has been documented in the research literature.

Frequently Asked Questions (FAQ)

Common questions about Fuxal (FAQ)

Q: How long does it typically take for Fuxal to start working?

Official documentation describes the medication's mechanism as causing rapid, non-specific binding to essential bacterial components after activation by bacterial enzymes. While this process is initiated quickly, a specific time frame for when a patient will feel or see the clinical effect is not defined in the prescribing information. Fuxal is used until the healthcare provider determines that the need for topical antimicrobial application has ended.

Q: Is Fuxal considered a long-term medication?

The official prescribing information indicates that Fuxal is intended for short-term use. The goal of treatment is to reduce local microbial load, and the medication should be discontinued once the need for topical antimicrobial application is resolved. It is not generally classified as a drug intended for prolonged, continuous use.

Q: Why do people sometimes say Fuxal 'didn't work' for them?

Official information on the drug's mechanism acknowledges that its physiological consequence is dependent on specific bacterial enzymes. If a strain of bacteria loses or significantly lowers the level of these required enzymes (a form of bacterial resistance), the drug may not be converted into its active form. This constraint is a factor that may restrict the physiological consequence of the drug's action against some susceptible strains.

Q: What kind of studies have been done on Fuxal?

Research evidence for Fuxal has included Randomized Controlled Trials (RCTs) and systematic reviews like meta-analyses. These studies have primarily investigated specific clinical endpoints, such as measuring changes in pain, inflammation, and predefined clinical scoring systems over specified periods of treatment.

Q: Is Fuxal habit-forming or addictive?

Fuxal's active ingredient, Nitrofural (nitrofurazone), is not classified or controlled under the Controlled Substances Act by regulatory bodies. This classification means the active ingredient does not fall under the legal identification as having potential for abuse or dependence.

Q: Does Fuxal show up on a standard drug test?

The active ingredient, Nitrofural, is rapidly metabolized by the body. However, one of its metabolites, semicarbazide (SEM), has been identified and historically used as a marker for the drug's presence in certain monitoring methods. Official prescribing information does not typically address the inclusion of the drug or its metabolites in common drug screening panels.

Q: What happens if I stop taking Fuxal suddenly?

Official guidelines state that Fuxal is for short-term use and should be discontinued when it is no longer needed for topical antimicrobial application. The regulatory labeling does not describe the need for a gradual reduction in use, or any specific withdrawal effects upon cessation.

Q: Are there any known interactions between Fuxal and herbal supplements?

Specific drug-drug or drug-herb interaction warnings are not typically listed in the official topical Nitrofural labeling. Regulatory standards highlight the importance of informing a healthcare provider about all products being used, including prescription, over-the-counter, or herbal supplements.

Q: Why is Fuxal taken at a specific time of day?

Official guidance specifies a typical application schedule of once daily, or sometimes once weekly, depending on the wound dressing technique being used. The frequency is regulated based on clinical protocol, but official documents do not regulate a specific time of day for application.

Q: How long does Fuxal stay in the system?

The parent compound, Nitrofural, is described as having a short half-life, indicating it is rapidly metabolized after absorption. While it is designed for minimal systemic absorption, its reactive breakdown products are known to bind to proteins and can be detectable for longer periods in toxicology and pharmacological studies.

Q: Are there any known interactions between Fuxal and common over-the-counter pain relievers?

Specific interactions with common over-the-counter pain relievers, such as NSAIDs, are not generally detailed in the official topical Nitrofural labeling. Official documents consistently emphasize the importance of consulting a healthcare provider about using all medications together.

Q: What are some less common but possible side effects of Fuxal?

Beyond the most frequently reported effect of contact dermatitis, the official safety profile documents other less common dermal reactions. These possible localized adverse effects have included pruritus (itching), rash, and swelling at the application site. Severe contact dermatitis is also documented.

Q: Why is monitoring sometimes required when using Fuxal?

A safety constraint is noted for patients with kidney impairment. Official guidance advises using caution with formulations that contain polyethylene glycol (PEG) over large damaged skin areas, due to the potential for PEG to be absorbed and accumulate in patients with known or suspected kidney impairment.

Q: What type of medical professional typically prescribes Fuxal?

Fuxal is classified as a prescription-only medication. This means it must be ordered and supervised by a licensed healthcare professional, such as a physician, nurse practitioner, or physician assistant, who are responsible for determining its appropriate use.

Q: Is there a generic version of Fuxal available?

The active ingredient in Fuxal is known internationally as Nitrofural (or nitrofurazone). The ingredient itself is commonly available as an Inn (International Non-proprietary Name) product, which is often referred to as a generic equivalent in various topical forms.

Q: Are there any long-term effects associated with Fuxal?

The official labeling contains a safety note concerning findings from high-dose animal carcinogenicity studies. Regulatory bodies state that the relevance of these findings to human topical use of the medication is officially unknown and is an area of ongoing surveillance.

Q: Is Fuxal a new medicine or has it been around for a while?

Nitrofural is an agent that has been approved and in use for many decades. While its regulatory status and specific applications have changed over time, the topical use of this compound has been a part of official regulatory action for a considerable duration.

Q: Is Fuxal approved in countries outside of the US?

The active ingredient is internationally recognized and has varying regulatory statuses globally. Approvals and restrictions are dependent on individual national health authorities, with the compound having classification under the WHO's ATC system.

How should Fuxal be stored and disposed of?

How to Store and Dispose of Fuxal?


Storage Guidelines

Store Fuxal in its original container, tightly closed, and keep it out of the reach of children and pets. The medication should be kept at room temperature and away from excess heat and moisture. A good storage location is typically a dresser drawer or a kitchen cabinet away from the stove, sink, and hot appliances. Avoid storing medication in the bathroom medicine cabinet, as the humidity and moisture from the shower and bath may damage the drug and reduce its effectiveness.

Disposal Instructions

Do not flush unused or expired Fuxal down the toilet or pour it down a drain unless specifically instructed to do so on the packaging. The best method for disposal is to use a drug take-back program, such as those provided by the DEA, local pharmacies, or law enforcement agencies. If a take-back program is unavailable, you may dispose of it in your household trash by mixing the tablets or capsules with an undesirable substance, such as dirt, cat litter, or used coffee grounds. Place this mixture in a sealed plastic bag or container before discarding it, and be sure to remove all personal information from the prescription label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fuxal found in:

A-Z Index: